Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04496934
Other study ID # 2013/00731
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 30, 2018
Est. completion date January 31, 2020

Study information

Verified date July 2020
Source Haukeland University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In terms of research, it is documented that exercise has a positive effect on mental disorders. Studies have shown positive correlations between physical and mental health, also among substance users. Such a study has never been performed on patients in opioid substitution therapy (OST). Documentation on the physical health of patients and the effect of exercise is very limited. Treatment of substance users is a research area with insufficient knowledge about certain treatment effects. It is important that a treatment can both support and promote the user's own resources and efforts to change their habits of substance use.

The objective of this project is to examine the effect of exercise for OST patients, measured in relation to cognitive function and physical form. The target group consists of OST patients from 18 years of age and up, of both sexes, and on stable medication. At least 60 participants should complete the project, which is designed as a controlled randomized study (RCT). Participants in the intervention group start to exercise immediately after baseline testing. Participants in the control group are on a waiting list and will start to exercise after twelve weeks. Both groups undergo testing at baseline, after three, six and 12 months. Testing consists of two parts: A battery of cognitive and psychosocial assessments and an assessment of physical variables.

The research questions of this project are important in a public health perspective. Generated knowledge can be quickly applied to local treatment institutions in Norway.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date January 31, 2020
Est. primary completion date January 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Participants must sign a informed consent form

- Must be participating in an opioid substitution program

- Must be on a steady fixed dose of medication

- Must be at least 18 years of age

Exclusion Criteria:

- Pregnancy

- Being in opioid substitution program for less than three months

Study Design


Intervention

Behavioral:
Exercise
Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.

Locations

Country Name City State
Norway Haukeland University Hospital Bergen

Sponsors (6)

Lead Sponsor Collaborator
Haukeland University Hospital Helse Stavanger HF, Kristiania University College, Solli Distriktspsykiatriske Senter, University of Bergen, Western Norway University of Applied Sciences

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Height and weight Weight and height will be combined to report BMI in kg/m^2 12 weeks
Primary Endurance Ventilatory threshold/VO2max (endurance test on treadmill) 12 weeks
Primary Strength Push-ups (maximal test where the participants perform a maximum number of correct push-ups) 12 weeks
Primary Balance Stork Balance Test (timed test where the goal is to keep one's balance as long as possible) 12 weeks
Secondary Alcohol use AUDIT-E 12 weeks
Secondary Drug use DUDIT-E 12 weeks
Secondary Executive functions Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) 12 weeks
Secondary Satisfaction with life Satisfaction With Life Scale (SWLS)
Values/scores:
7 - Strongly agree
6 - Agree
5 - Slightly agree
4 - Neither agree nor disagree
3 - Slightly disagree
2 - Disagree
1 - Strongly disagree
Results (sum of scores/values):
31 - 35 Extremely satisfied 26 - 30 Satisfied 21 - 25 Slightly satisfied 20 Neutral 15 - 19 Slightly dissatisfied 10 - 14 Dissatisfied 5 - 9 Extremely dissatisfied The higher the score the better the outcome.
12 weeks
Secondary Sleep quality Pittsburgh Sleep Quality Index (PSQI) 12 weeks
Secondary Attention Connors Continuous Performance Test (CPT 3) 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05660434 - Using Aromatherapy in Substance Use Disorder N/A
Active, not recruiting NCT05338268 - Substance Use and Loneliness N/A
Completed NCT04098614 - Barriers to Substance Use Disorder Recovery N/A
Completed NCT03954184 - E-health Implementation (Iowa) N/A
Completed NCT03590106 - Cardiac Surgery Peer Recovery Support Program N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Terminated NCT03517111 - The Impact of a Parenting Intervention on Latino Youth Health Behaviors N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04401215 - Technologically-Augmented Referrals to Mitigate Addiction Consequences N/A
Not yet recruiting NCT06187701 - Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Active, not recruiting NCT02382042 - Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans N/A
Terminated NCT01356667 - Drum-Assisted Therapy for Native Americans N/A
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Completed NCT00708890 - Twelve Step Based Self-help Groups for Substance Related Disorders N/A
Active, not recruiting NCT04048850 - Zepatier in Patients With Substance Use
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2